New Zealand markets closed

NVS Jan 2023 82.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
9.700.00 (0.00%)
As of 01:29PM EST. Market open.
Full screen
Previous close9.70
Open9.50
Bid0.00
Ask0.00
Strike82.50
Expiry date2023-01-20
Day's range9.50 - 9.70
Contract rangeN/A
Volume2
Open interest870
  • GlobeNewswire

    Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

    Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca’s addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerci

  • Zacks

    Novartis' (NVS) PNH Candidate Achieves Study Objectives

    Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.

  • GlobeNewswire

    Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

    Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH)1Topline APPOINT-PNH data were consistent with APPLY-PNH readout and showed a significant proportion of complement-inhibitor-naïve patients treated with iptacopan achieved clinically meaningful increases in hemoglobin levels vs. baseline without the need for blood transfusions1PNH has a significant